Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development.
On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.
Table of Contents
|2 Overview of Key Issues||6-16|
|3 Cardiac Safety Biomarkers||17-28|
|4 Assessing and Predicting Kidney Safety||29-41|
|5 Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials||42-57|
|6 Future Considerations||58-64|
|Appendix A: Workshop Agenda||65-70|
|Appendix B: Speaker Biographies||71-84|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary...